Advances in pathogenesis and treatment of dermatofibrosarcoma protuberans
10.3760/cma.j.cn114453-20210607-00251
- VernacularTitle:隆突性皮肤纤维肉瘤发病机制及治疗进展
- Author:
Youxin CHEN
1
;
Zhen CAI
Author Information
1. 遵义医科大学，贵州 563006
- Keywords:
Sarcoma;
Cutaneous fibrous histiocytoma;
Dermatofibrosarcoma protuberans;
Molecular targeted therapy
- From:
Chinese Journal of Plastic Surgery
2022;38(6):729-734
- CountryChina
- Language:Chinese
-
Abstract:
Dermatofibrosarcoma protuberans (DFSP) is a kind of locally invasive skin soft tissue sarcoma originating from fibroblasts. DFSP has a high local recurrence rate and a low metastatic rate, the diagnosis of typical DFSP is mainly based on histopathological examination. The treatment of DFSP is still dominated by extensive local resection of the tumor, but Mohs microsurgery, which is more effective, has been adopted by more and more clinicians. Adjunctive therapy for DFSP includes molecular targeted therapy, radiotherapy, chemotherapy and cryoablation etc. Retinoic acid drugs and antiangiogenic drug apatinib have been reported as potential therapeutic agents for DFSP. In this review, the pathogenesis, clinical manifestations, diagnosis and treatment of DFSP are reviewed to provide reference for clinical diagnosis and treatment of DFSP.
